Comparative Pharmacology
Head-to-head clinical analysis: PEG 3350 AND ELECTROLYTES versus PLEGISOL IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEG 3350 AND ELECTROLYTES versus PLEGISOL IN PLASTIC CONTAINER.
PEG 3350 AND ELECTROLYTES vs PLEGISOL IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PEG 3350 is an osmotic laxative that retains water in the bowel lumen via hydrogen bonding, increasing fecal water content and stimulating peristalsis. Electrolytes (sodium sulfate, potassium chloride, sodium bicarbonate, magnesium sulfate) prevent significant fluid and electrolyte shifts by maintaining isotonicity.
PLEGISOL is an extracellular-type crystalloid cardioplegic solution used for myocardial protection during cardiac surgery. Its mechanism involves inducing rapid cardiac arrest by high potassium concentration (depolarizing arrest), reducing myocardial oxygen demand, and providing buffering capacity via tromethamine to maintain pH. The solution also contains magnesium to stabilize membranes and mannitol as an osmotic agent to reduce edema.
4 liters orally of the reconstituted solution administered as a single dose at 240 mL every 10 minutes or 1 to 1.5 L/hour until rectal effluent is clear. Alternatively, 240 mL every 10 minutes until 4 L consumed.
Administered as an intraperitoneal infusion for organ preservation. Typical adult dose: 2.5-3.0 liters for kidney, 2.5-3.0 liters for liver, 3.0-4.0 liters for pancreas, single dose prior to procurement.
None Documented
None Documented
Not applicable; PEG 3350 undergoes minimal systemic absorption (<0.2%), thus no meaningful terminal half-life. Systemic half-life of absorbed fraction is <2 hours.
Not applicable; Plegisol is not a systemically active drug. Its cardioplegic effect is immediate upon perfusion into coronary arteries and dissipates upon reperfusion. The solution's components have endogenous half-lives (e.g., potassium: 1-1.5 h in plasma), but this is not clinically relevant for the product.
Primarily fecal (96–98%) as unabsorbed PEG 3350; electrolytes absorbed are excreted renally (sodium, potassium) and via feces (biliary excretion negligible).
Plegisol is an extracellular cardioplegic solution; its components (electrolytes and calcium) are not metabolized. Elimination of infused volume occurs primarily via renal excretion (approx. 95%) as unchanged water and electrolytes; minor biliary/fecal elimination (<5%) accounts for negligible electrolyte loss.
Category C
Category C
Osmotic Laxative
Osmotic Laxative